BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 09, 2004
 |  BioCentury  |  Emerging Company Profile

TargeGen: The vascular biologists

Venture capital firm Forward Ventures formed TargeGen Inc. because the firm perceived that vascular biology was an under-exploited means of developing therapies in the cardiovascular and cancer fields. Based on a basket of intellectual property in-licensed from Merck KGaA, TargeGen develops small molecules aimed at kinases late in the molecular cascade that results in increased vascular permeability.

President and CEO Peter Ulrich, formerly an "entrepreneur in residence" at Forward Ventures, said the concept for the company was the product of the VC's interest in vascular biology and its desire to implement a new model for creating companies. Instead of reacting to business plans sent to the firm, Ulrich said, Forward wanted to identify areas of unmet need on its own and form companies around them.

The search for experts in vascular biology led to the laboratory of David Cheresh at Scripps Research Institute...

Read the full 710 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >